Thursday, 18 July 2019
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (CSE: $KBEV.C) (OTC: $KALY) (OTC: $PURA) (NASDAQ: $NEPT) (NYSE: $ACB) (CSE: $OH.C) (TSX: $APHA.TO)
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (CSE: $KBEV.C) (OTC: $KALY) (OTC: $PURA) (NASDAQ: $NEPT) (NYSE: $ACB) (CSE: $OH.C) (TSX: $APHA.TO)
Delta, Kelowna, BC –July 18, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/07181KBEV-KALY-PURA-NEPT-ACB-OH-APHA.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “potcasts”, looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few early announcements.
Koios Beverage Corp. (CSE: KBEV) (OTC: KBEVF) announced that it has made several key developments with respect to its proposed line of functional beverages containing broad-spectrum hemp extract CBD. In a press release dated September 4, 2018, the Company announced its plans to release a functional beverage, which would be infused with CBD to enhance the beverage's effects. Koios will leverage its existing relationship with Colorado-based Keef Brands in the development of this product, with Keef Brands to supply crystalized, water-soluble CBD which will be added to Koios' existing Fit SodaTM line of functional beverages. Starting tomorrow, the Company and Keef Brands will produce several test batches of the proposed CBD beverage, with user trials to begin shortly afterward.
The addition of CBD to Koios' proprietary stack of nutrients, amino acids, and electrolytes in its Fit SodaTM line of beverages is expected to improve the product's effects. Pending completion of further testing, the Company also plans to integrate CBD into its eponymous KOIOS beverage lineup at a later date. When the proposed beverage is released, Fit SodaTM will be available both with and without CBD.
On Friday, July 19, 2019, Koios will start production of several test batches of its Fit SodaTM product with crystallized CBD supplied by Keef Brands. Upon completion of this production, the Company will be distributing the products from the test batch to select existing clients for trial purposes. Additionally, Koios has consumer trials planned with individuals in its local community. Feedback derived from these trials will be utilized to further develop the proposed CBD beverage and prepare it for commercial production and distribution under the Fit SodaTM banner. The water-soluble CBD crystals supplied through Keef Brands have shown consistent potency and efficacy results in Keef's internal evaluation efforts of numerous water-soluble CBD solutions over the past year.
Large-scale distribution of CBD-enhanced Fit SodaTM will be contemplated by Koios based on feedback that the Company receives from the test batches being produced beginning tomorrow. Developments with respect to this large-scale distribution, including interest received from retail vendors, will be announced in a future press release.
Koios Chief Executive Officer Chris Miller added, "I believe we made the right choice with respect to waiting until now to finalize our development of a CBD-enhanced functional beverage. Between an ambiguous legal landscape for CBD, as well as an unbelievable amount of pseudoscience and false claims about this cannabinoid, last year simply was not the right time for us to finalize such a product or bring it to market. By holding off, we have been able to put our full focus on our existing products and relationships with large-scale retailers. Additionally, it gave us the opportunity to observe others' successes and failures in developing or releasing CBD products, from which we are learning, for when we ultimately release our beverages with CBD. We are thankful for being able to continue working with Keef Brands as such a highly-respected firm in the beverages space, and we are eagerly anticipating positive results from the test batch trials."
Kali-Extracts (OTC: KALY) announced today that the company is working with its partner Puration, Inc. (OTC: PURA) on developing a CBD extraction for PURA’s plans to introduce a CBD infused beer with an existing beer producer. KALY has a U.S. Patent for Cannabis Extraction and partners with PURA now on 10 mg and 25 mg CBD infused sports beverages. PURA is a leading CBD infused beverage company having produced over $1 million in CBD Beverages in the United States last year. PURA has targeted $4 million in sales for 2019.
A research report out this week highlights the current alcohol producer trend to pursue cannabis beverages with the continued liberalization of cannabis laws.
KALY is primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas.
KALY has a deep pipeline of cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabis worldwide, announced today that the Company has been selected as the only winner of the Italian government's public tender to supply medical cannabis in Italy. The supply contract is expected to be signed in September 2019.
The tender saw five companies participate, with Aurora selected as the sole winner of three lots to supply the Italian market, which is one of the most strictly regulated medical cannabis markets in the world. The decision will see Aurora continue to supply the Italian market with medical cannabis, as it has done for the past 15 months, further to winning the first ever tender there in January 2018. All submissions from competing cannabis companies were disqualified because they were unable to meet the stringent requirements of the tender.
Aurora will supply a minimum of 400 kg of medical cannabis over the two-year contract with the cannabis coming from its Canadian EU GMP certified facilities and imported to Italy through Aurora Deutschland, its wholly-owned European subsidiary. The cannabis will be sold to Agenzia Industrie Difesa (an agency of the Italian Ministry of Defense) for distribution to local pharmacies, who dispense directly to patients.
"We're committed to building a successful, long-term medical cannabis market in Italy," said Neil Belot, Aurora's Chief Global Business Development Officer. "We want to continue to build our connection with patients and pharmacies in the Italian market, who have come to know and appreciate our products over most of the past two years. I'm extremely proud of our team. This win reflects our ability to navigate complex international regulations and work with governments around the world to establish ourselves as a trusted partner."
Axel Gille, Managing Director of Aurora Deutschland GmbH, added, "The well-being of our patients is our top priority and we're dedicated to ensuring they have access to a consistent supply of safe, high-quality medical cannabis. We look forward to expanding our presence in Italy and continuing to work with other international regulators to ensure patients around the world have access to our high-quality medical cannabis."
Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), a North American leader in cannabinoids extraction, formulation and turnkey packaging solutions, has completed a private placement with both existing and new institutional investors, led by Perceptive Advisors, resulting in gross proceeds to the Company of US$41.4 million. John Moretz, Chairman of the Board, and Michael Cammarata, President and CEO of Neptune, invested US$5.0 million in the aggregate as part of this Offering. Upon closing of the Offering, the Company issued an aggregate of 9,415,910 common shares of the Company at a purchase price of US$4.40 per Share.
"The Board joins me in thanking investors who participated in this offering and in welcoming our new shareholders to Neptune. Given recent contracts and the announced extraction capacity expansion plans, we are highly confident in the strength of Neptune's business outlook", said John Moretz. "My incremental investment in Neptune reflects my conviction in our new CEO and management team and their ability to execute on Neptune's strategy. We opted for this accelerated financing structure to stay on track with the previously announced SugarLeaf closing timeline."
A portion of the net proceeds from the Offering is expected to be used by the Company to fund the initial consideration for the acquisition of the assets of SugarLeaf Labs LLC and Forest Remedies LLC (collectively "SugarLeaf"), while the balance of such net proceeds is expected to be used for working capital and general corporate purposes. Neptune expects the SugarLeaf transaction to close on or before July 31, 2019.
"This financing comes at a pivotal point in the Company's cannabis growth trajectory, particularly given the need to expand our current annual capacity of 200,000 kg, which is fully contracted for both fiscal 2020 and fiscal 2021," said Mr. Cammarata. "With this in mind, we look forward to closing the SugarLeaf transaction, which brings U.S.-based capacity, efficient production of high-quality extracts, and strong supplier relationships, all of which create a strong value proposition for our customers."
CannaRoyalty Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF), a North American cannabis products and brands company today announced preliminary unaudited revenue of approximately $21 million1 for the second quarter ended June 30, 2019, at an approximate gross margin, excluding fair value items, of 17%1. All figures are reported in Canadian dollars, unless otherwise indicated.
The California market has grown in 2019, with an increase in the number of licensed dispensaries since December 20182 and a more stable regulatory environment than in 2018. Origin House's progress during the first six months of the year has primarily been driven by its focused strategy to capitalize on the statewide California platform it established over the past two years.
Marc Lustig, Chairman and CEO of Origin House commented, "Origin House has continued to gain momentum as our team leveraged the California-focused platform we have built over the past two years to drive another quarter of record revenue along with steady progress on gross margin. As expressed previously, we strongly believe that 2019 will mark an inflection point both for the California market and Origin House as a whole and the numbers are proving this out."
Origin House plans to release its full financial results for the second quarter ended June 30, 2019 during the second half of August and will be coordinating its financial results release with the release of Cresco Labs' financial results.
Aphria Inc. (TSX: APHA) (NYSE: APHA) will release results for the fourth quarter and twelve months ended May 31, 2019 on August 1, 2019 after market close.
Aphria executives will host a conference call to discuss these results at 5:00 pm ET. To listen to the live call, dial (888) 231-8191 from Canada and the U.S. or (647) 427-7450 from International locations and use the passcode 5081017. A telephone replay will be available approximately two hours after the call concludes through August 15, 2019. To access the recording dial (855) 859-2056 and use the passcode 5081017.
There will also be a simultaneous live webcast available on the Investors section of Aphria's website at aphriainc.com. The webcast will be archived for 30 days.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Sign up to get the news alerts including the daily podcast and transcript for Investor ideas podcasts
Subscribe to the new cannabis podcast series:
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com
Follow us on Social Media
Investorideas.com - Cannabis Stock News: Fiore Cannabis (CSE: FIOR) Relaunches Diamante Extraction Lab to Satisfy Growing Demand in Nevada Market
Investorideas.com - Cannabis Stock News: Fiore Cannabis (CSE: FIOR) Relaunches Diamante Extraction Lab to Satisfy Growing Demand in Nevada M...
Investorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains ListInvestorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains List
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Aurora Cannabis (TSX: $ACB.TO) (NYSE: $ACB), Khiron Life Sciences (TSXV: $KHRN.V), (OTCQB: $KHRNF), Cannabis One Holdings (CSE: $CBIS.C), Liht Cannabis (CSE: $LIHT.C) and FSD Pharma (CSE: $HUGE.C) (OTCQB: $FSDDF)Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Aurora Cannabis (TSX: $ACB.TO) (NYSE: $ACB), Khiron Life Sciences (TSXV:...
Investorideas.com - #Cannabisstocks: Rapid Dose Therapeutics (CSE: DOSE) and Thrive Cannabis Sign MOU to Provide Quickstrip(TM) Oral Thin Strips Under a White Label Manufacturing AgreementInvestorideas.com - #Cannabisstocks: Rapid Dose Therapeutics (CSE: DOSE) and Thrive Cannabis Sign MOU to Provide Quickstrip(TM) Oral Thin St...